Department of Internal Medicine II Department of Hematology and Internal Oncology University Hospital Jena Am Klinikum 1, 07747 Jena Phone: +49 3641 9 324 201 Fax: +49 3641 9 324 202 andreas.hochhaus@med.uni-jena.de Homepage
Functions
Director of the Department of Hematology and Internal Oncology of KIM II
Speaker of the University Tumor Center
Vice Dean for Research
Research
Chronic myeloid leukemia
Chronic myeloproliferative disorders
Minimal residual disease
signaling
Publications (the 5 most important)
Saussele S, Richter J, Guilhot J, ..., Hochhaus A, Pfirrmann M, Mahon FX: "Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial" Lancet Oncol. 2018 Jun;19(6):747-757
Xiao G, ... Ernst T, Hochhaus A, ..., Müschen M. "B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies" Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048.
Mathew NR, ..., Hilgendorf I, Hochhaus A, .... Zeiser R. "Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells" Nat Med. 2018 Mar;24(3):282-291.
Hochhaus A, Larson RA, Guilhot F, et al. "Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia" N Engl J Med. 2017 Mar 9;376(10):917-927.
Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T. "Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms" Leukemia. 2017 Sep;31(9):1936-1943.